These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

74 related articles for article (PubMed ID: 29607903)

  • 1. Effects of the Chemical Structures of Oligoarginines Conjugated to Biocompatible Polymers as a Mucosal Adjuvant on Antibody Induction in Nasal Cavities.
    Mohri K; Miyata K; Egawa T; Tanishita S; Endo R; Yagi H; Ukawa M; Ochiai K; Hiwatari KI; Tsubaki K; Shigeno K; Tobita E; Uto T; Baba M; Sakuma S
    Chem Pharm Bull (Tokyo); 2018; 66(4):375-381. PubMed ID: 29607903
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biodegradable Hyaluronic Acid Modified with Tetraglycine-l-octaarginine as a Safe Adjuvant for Mucosal Vaccination.
    Ukawa M; Tanishita S; Yagi H; Yoshida Y; Tomono T; Shigeno K; Tobita E; Uto T; Baba M; Sakuma S
    Mol Pharm; 2019 Mar; 16(3):1105-1118. PubMed ID: 30715891
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Demonstration of d-Octaarginine-Linked Polymers as Promising Adjuvants for Mucosal Vaccination through Influenza Virus Challenge.
    Miyata K; Mohri K; Egawa T; Endo R; Morimoto N; Ochiai K; Hiwatari K; Tsubaki K; Tobita E; Uto T; Baba M; Sakuma S
    Bioconjug Chem; 2016 Aug; 27(8):1865-71. PubMed ID: 27463562
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cross-reactivity of immunoglobulin A secreted on the nasal mucosa in mice nasally inoculated with inactivated H1N1 influenza A viruses in the presence of D-octaarginine-linked polymers.
    Sakuma S; Morimoto N; Nishida K; Murakami T; Egawa T; Endo R; Kataoka M; Yamashita S; Miyata K; Mohri K; Ochiai K; Hiwatari K; Koike S; Tobita E; Uto T; Baba M
    Eur J Pharm Biopharm; 2015 May; 92():56-64. PubMed ID: 25720816
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cell-penetrating peptide-linked polymers as carriers for mucosal vaccine delivery.
    Sakuma S; Suita M; Inoue S; Marui Y; Nishida K; Masaoka Y; Kataoka M; Yamashita S; Nakajima N; Shinkai N; Yamauchi H; Hiwatari K; Tachikawa H; Kimura R; Uto T; Baba M
    Mol Pharm; 2012 Oct; 9(10):2933-41. PubMed ID: 22953762
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oligoarginine-linked polymers as a new class of penetration enhancers.
    Sakuma S; Suita M; Masaoka Y; Kataoka M; Nakajima N; Shinkai N; Yamauchi H; Hiwatari K; Tachikawa H; Kimura R; Yamashita S
    J Control Release; 2010 Dec; 148(2):187-96. PubMed ID: 20800631
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cross-Protective Abilities of Hyaluronic Acid Modified with Tetraglycine-l-octaarginine as a Mucosal Adjuvant against Infection with Heterologous Influenza Viruses.
    Tanishita S; Ukawa M; Tomono T; Yoshida Y; Tsujioka T; Miyata K; Tobita E; Uto T; Baba M; Sakuma S
    Bioconjug Chem; 2019 Dec; 30(12):3028-3037. PubMed ID: 31738536
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mechanism on antigen delivery under mucosal vaccination using cell-penetrating peptides immobilized at multiple points on polymeric platforms.
    Ukawa M; Endo R; Yagi H; Tomono T; Miyata K; Shigeno K; Tobita E; Uto T; Baba M; Sakuma S
    Int J Pharm; 2022 Feb; 613():121376. PubMed ID: 34915143
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Protective immunity against influenza H5N1 virus challenge in mice by intranasal co-administration of baculovirus surface-displayed HA and recombinant CTB as an adjuvant.
    Prabakaran M; Velumani S; He F; Karuppannan AK; Geng GY; Yin LK; Kwang J
    Virology; 2008 Oct; 380(2):412-20. PubMed ID: 18786689
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of poly[di(sodium carboxylatophenoxy)phosphazene] (PCPP) as mucosal adjuvant to induce protective immunity against respiratory pathogens.
    Shim DH; Ko HJ; Volker G; Potter AA; Mutwiri G; Babiuk LA; Kweon MN
    Vaccine; 2010 Mar; 28(11):2311-7. PubMed ID: 20060944
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Validation of the Absorption-Enhancing Ability of Oligoarginines Grafted onto a Backbone of Hyaluronic Acid through Animal Studies from Rodents to Primates.
    Yagi H; Tomono T; Abe K; Tsutsumi Y; Makabe M; Mitsuhashi H; Kimura T; Kobayashi H; Miyata K; Shigeno K; Sakuma S
    Mol Pharm; 2024 Jul; 21(7):3485-3501. PubMed ID: 38804275
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biocompatible Polymers Modified with d-Octaarginine as an Absorption Enhancer for Nasal Peptide Delivery.
    Miyata K; Ukawa M; Mohri K; Fujii K; Yamada M; Tanishita S; Higashitarumi S; Ishizaki S; Kumagai H; Ochiai K; Hiwatari KI; Tsubaki K; Shigeno K; Tobita E; Kobayashi H; Sakuma S
    Bioconjug Chem; 2018 May; 29(5):1748-1755. PubMed ID: 29648441
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bacterium-like particles supplemented with inactivated influenza antigen induce cross-protective influenza-specific antibody responses through intranasal administration.
    de Haan A; Haijema BJ; Voorn P; Meijerhof T; van Roosmalen ML; Leenhouts K
    Vaccine; 2012 Jul; 30(32):4884-91. PubMed ID: 22537989
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Consecutive inoculations of influenza virus vaccine and poly(I:C) protects mice against homologous and heterologous virus challenge.
    Moriyama M; Chino S; Ichinohe T
    Vaccine; 2017 Feb; 35(7):1001-1007. PubMed ID: 28111142
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intranasal Immunization Using Mannatide as a Novel Adjuvant for an Inactivated Influenza Vaccine and Its Adjuvant Effect Compared with MF59.
    Ren ST; Zhang XM; Sun PF; Sun LJ; Guo X; Tian T; Zhang J; Guo QY; Li X; Guo LJ; Che J; Wang B; Zhang H
    PLoS One; 2017; 12(1):e0169501. PubMed ID: 28052136
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intranasal administration of a flagellin-adjuvanted inactivated influenza vaccine enhances mucosal immune responses to protect mice against lethal infection.
    Hong SH; Byun YH; Nguyen CT; Kim SY; Seong BL; Park S; Woo GJ; Yoon Y; Koh JT; Fujihashi K; Rhee JH; Lee SE
    Vaccine; 2012 Jan; 30(2):466-74. PubMed ID: 22051136
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nasal absorption enhancement of protein drugs independent to their chemical properties in the presence of hyaluronic acid modified with tetraglycine-L-octaarginine.
    Tomono T; Yagi H; Ukawa M; Ishizaki S; Miwa T; Nonomura M; Igi R; Kumagai H; Miyata K; Tobita E; Kobayashi H; Sakuma S
    Eur J Pharm Biopharm; 2020 Sep; 154():186-194. PubMed ID: 32681963
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intranasal vaccination of recombinant H5N1 HA1 proteins fused with foldon and Fc induces strong mucosal immune responses with neutralizing activity: Implication for developing novel mucosal influenza vaccines.
    Yu F; Li Y; Guo Y; Wang L; Yang J; Zhao G; Zhou Y; Du L; Jiang S
    Hum Vaccin Immunother; 2015; 11(12):2831-8. PubMed ID: 26260706
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The use of a mutant TNF-alpha as a vaccine adjuvant for the induction of mucosal immune responses.
    Kayamuro H; Abe Y; Yoshioka Y; Katayama K; Nomura T; Yoshida T; Yamashita K; Yoshikawa T; Kawai Y; Mayumi T; Hiroi T; Itoh N; Nagano K; Kamada H; Tsunoda S; Tsutsumi Y
    Biomaterials; 2009 Oct; 30(29):5869-76. PubMed ID: 19646748
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Alkyl polyglycoside, a highly promising adjuvant in intranasal split influenza vaccines.
    Wu H; Bao Y; Wang X; Zhou D; Wu W
    Hum Vaccin Immunother; 2017 Jun; 13(6):1-9. PubMed ID: 28129034
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.